[The new pathogenetic agent lipin for the treatment of patients with respiratory failure].
Results are submitted of clinical trial of a new drug preparation lipin based on natural phospholipids. Overall fifty-three patients with various disorders of the respiratory system complicated by the respiratory distress syndrome received the drug. Lipin was found to have a positive effect on pulmonary ventilation and oxygen-transport functions, thereby lessening arterial hypoxemia. The drug preparation in question appeared to be of clinical benefit in as many as 94.3 percent of the patients. It is concluded that lipin is worthy to come into widespread use in a variety of settings in medicine.